Thiadiazoline derivative
US7759371B2 · kind B2 · utility
2Cited by
19References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 7, 2008 |
| Grant date | Jul 20, 2010 |
| Priority date | — |
| Expiry date | Apr 7, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
(wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(═W)R6 or the like; R3 represents a hydrogen atom, —C(═WA)R6A, or the like)Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.